Leap Therapeutics, Inc.
Leap Therapeutics is a Cambridge, United States-based company focused on developing targeted and immuno-oncology therapeutics.
Last updated September 15, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Leap Therapeutics is focused on developing targeted and immuno-oncology therapeutics. Its most advanced clinical candidate, sirexatamab (DKN-01), is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, being developed in patients with colorectal, esophagogastric, and gynecologic cancers. Leap also has FL-501, a humanized monoclonal antibody targeting the growth and differentiation factor 15 (GDF-15) protein, in preclinical development.
History
Leap Therapeutics is focused on developing targeted and immuno-oncology therapeutics. Its most advanced clinical candidate, sirexatamab (DKN-01), is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, and is being developed in patients with colorectal, esophagogastric, and gynecologic cancers. The company also has FL-501, a humanized monoclonal antibody targeting the growth and differentiation factor 15 (GDF-15) protein, in preclinical development. The company has announced publication of DeFianCe Study results in Clinical Cancer Research and presented final data from the DeFianCe Study at ESMO 2025.
Products and positioning
Focused on developing targeted and immuno-oncology therapeutics.
Sirexatamab (DKN-01)
A humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, being developed in patients with colorectal, esophagogastric, and gynecologic cancers.
FL-501
A humanized monoclonal antibody targeting the growth and differentiation factor 15 (GDF-15) protein, in preclinical development.
Sources3 sources
Cite this profile: Cite the canonical profile. /brand-wiki/leap-therapeutics-inc-united-states · Editorial policy · How profiles are compiled